

# ASX ANNOUNCEMENT

8 February 2022

## Anteris Receives Proposal to Negotiate Non-Binding Letter of Intent for Merger

**Brisbane, Australia and Minneapolis, USA**, Anteris Technologies Ltd (ASX: AVR) (**Company**) announces that it has received a confidential, non-binding proposal to negotiate a letter of intent, which letter sets out a proposal to merge with NASDAQ-listed special purpose acquisition company Medicus Sciences Acquisition Corp. (**MSAC**). MSAC currently has no commercial operations and was established as a blank cheque company for the purpose of, amongst other things, effecting a merger, share exchange or business combination with one or more businesses.

The proposed transaction is a business combination whereby all existing Anteris shareholders will receive shares in MSAC in exchange for their shares in the Company by MSAC, to be implemented via a court-approved scheme of arrangement (**Proposal**). The Proposal contemplates an issuance of new equity by MSAC in exchange for the current shares in the Company at an equivalent value and stipulates that post-transaction the merged entity would have a minimum of \$US50M in cash, plus the existing funds held by the Company.

The board of the Company is considering the Proposal. There is no certainty at this time that:

- the Company will proceed with the Proposal;
- a binding offer from MSAC will be forthcoming; or
- the Proposal will result in any transaction occurring.

Shareholders are not required to take any action in relation to the Proposal at this time.

The Company will continue to update the market in due course in line with its continuous disclosure obligations.

**ENDS**

### About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company that delivers clinically superior and durable solutions through better science and better design.

Its focus is developing next-generation technologies that help healthcare professionals reproduce consistent life-changing outcomes for patients.

Anteris' DurAVR™ 3D single-piece aortic heart valve replacement addresses the needs of tomorrow's younger and more active aortic stenosis patients by delivering superior performance and durability through innovations designed to last the remainder of a patient's lifetime.

#### Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

#### Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E [info.au@anteristech.com](mailto:info.au@anteristech.com) | W [anteristech.com](http://anteristech.com)

Brisbane • Minneapolis • Geneva • Malaga





The proven benefits of its patented ADAPT<sup>®</sup> tissue technology, paired with the unique design of our DurAVR<sup>™</sup> 3D single-piece aortic heart valve, have the potential to deliver a game-changing treatment to aortic stenosis patients worldwide and provide a much-needed solution to the challenges facing doctors today.

**Authorisation and Additional information**

This announcement was authorised by the Board of Directors.

**For more information:**

Hannah Howlett

WE Communications

E: [WE-AUAnterisTech@we-worldwide.com](mailto:WE-AUAnterisTech@we-worldwide.com)

P: +61 4 5064 8064

[www.anteristech.com](http://www.anteristech.com)

Twitter: [@AnterisTech](https://twitter.com/AnterisTech)

Facebook: [www.facebook.com/AnterisTech](https://www.facebook.com/AnterisTech)

LinkedIn: <https://www.linkedin.com/company/anteristech>

